<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000762</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-20-10-2833</org_study_id>
    <nct_id>NCT05000762</nct_id>
  </id_info>
  <brief_title>Zinc Supplementation Improves Cardiovascular Morbidity in Patients With Diabetes Mellitus</brief_title>
  <official_title>Zinc Supplementation Improves Cardiovascular Morbidity in Patients With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>QPathology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral zinc supplementation in patients with diabetes mellitus can improve glycemic control.&#xD;
      However, there is reluctance to recommend zinc supplements to these patients because there is&#xD;
      no evidence that the zinc-dependent improvement in glycemic control offers protections from&#xD;
      the cardiovascular morbidities associated with diabetes mellitus, especially myocardial&#xD;
      infarction and thrombotic stroke. The investigators are conducting a randomized, double&#xD;
      blind, cross over study to test the hypothesis that oral zinc supplementation will block the&#xD;
      enhanced cardiovascular, cerebrovascular, and platelet reactivity that lead to myocardial&#xD;
      infarction and stroke in research participants with diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes mellitus induces adverse changes in the systemic blood vessels, the cerebral&#xD;
      vasculature, and platelets that can culminate in myocardial infarction and thrombotic stroke.&#xD;
      Also, when compared to patients whose diabetes mellitus is well controlled, poor glucose&#xD;
      maintenance in men and women with diabetes mellitus undeniably confers a much greater risk of&#xD;
      myocardial infarction and stroke. For these reasons, it is important to maintain euglycemia&#xD;
      in patients with diabetes mellitus. Several studies have shown supplemention with oral zinc&#xD;
      improves glycemic control in patients with diabetes mellitus. Zinc supplementation has been&#xD;
      associated with an absolute fall in glycosylated hemoglobin (HgbA1c), a measurement of&#xD;
      metabolic control, by 0.5 percentage points. It is unknown whether this dietary supplement&#xD;
      improves the exaggerated systemic and cerebrovascular and platelet responsiveness that are&#xD;
      responsible for the increased prevalence of myocardial infarction and stroke in patients with&#xD;
      diabetes mellitus. The investigators postulate that zinc dietary supplementation, when&#xD;
      compared to placebo, will significantly reduce the increased cardiovascular reactivity and&#xD;
      thrombogenesis associated with myocardial infarction or stroke in men and women with diabetes&#xD;
      mellitus. The investigators will conduct a randomized, double-blinded, cross over study in&#xD;
      volunteers with diabetes mellitus in which the participants receive either four months of&#xD;
      placebo or oral zinc gluconate (30 mg zinc gluconate). Subjects will have validated,&#xD;
      non-invasive, non-pharmacologic assessments of both their systemic and cerebrovascular&#xD;
      reactivity and platelet responsiveness. The investigators anticipate that zinc&#xD;
      supplementation will enhance flow mediated endothelium-dependent vasodilation in the&#xD;
      peripheral vasculature in patients with diabetes mellitus, and also, reduces cardiovascular&#xD;
      responses to stress. It is expected that zinc supplementation will blunt the magnitude of&#xD;
      blood pressure increases induced by exercise in the research subjects. Also, the&#xD;
      investigators expect to show that zinc supplementation, when compared to placebo, reduces&#xD;
      pulse wave velocity, a measure of vascular stiffness, in the research subjects with diabetes&#xD;
      mellitus. The investigators will show that zinc supplementation, when compared to placebo,&#xD;
      improves cerebral blood flow in patients with diabetes mellitus. The investigators will&#xD;
      assess cerebrovascular reactivity by measuring the sensitivity of intracerebral blood vessels&#xD;
      to increasing concentrations of pCO2, a maneuver which selectively relaxes the cerebral&#xD;
      vasculature and increases cerebral blood flow. Finally, the investigators anticipate that&#xD;
      zinc supplementation will reduce platelet aggregation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>4 months</time_frame>
    <description>Measure changes non-invasively wtihcarotid-femoral pulse wave velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebrovascular reactivity</measure>
    <time_frame>4 months</time_frame>
    <description>Measure vasodilation in response to increasing pCO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure response to exercise</measure>
    <time_frame>4 months</time_frame>
    <description>Assess blood pressure response to hand grip exercise</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet aggregation</measure>
    <time_frame>4 months</time_frame>
    <description>Measure catecholamine-induced platelet aggregation ex vivo</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Patients with diabetes mellitus</arm_group_label>
    <description>Patients with type 2 diabetes mellitus</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <description>Zinc gluconate 30 mg/day orally</description>
    <arm_group_label>Patients with diabetes mellitus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men and women between the ages of 18 - 75 years who have stable type 2 diabetes or&#xD;
        pre-diabetes reflected by a glycosylated heoglobin A1C between 6% - 9%. On no prescription&#xD;
        medications other than for diabetes mellitus or nutritional supplements containing zinc&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Only patients with stable type 2 diabetes mellitus or pre-diabetes (HgbA1c between 6%&#xD;
             - 9%) and who are otherwise healthy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Anyone unable to understand or give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren Lockette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Warren Lockette, MD</last_name>
    <phone>313 745-4008</phone>
    <email>ab1289@wayne.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wayne State University School of Medicine</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Warren Lockette, MD</last_name>
      <phone>313-745-4008</phone>
      <email>ab1289@wayne.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jayawardena R, Ranasinghe P, Galappatthy P, Malkanthi R, Constantine G, Katulanda P. Effects of zinc supplementation on diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2012 Apr 19;4(1):13. doi: 10.1186/1758-5996-4-13.</citation>
    <PMID>22515411</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Warren Lockette, M.D.</investigator_full_name>
    <investigator_title>Professor of Medicine and Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Zinc dietary supplement</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>cardiovascular reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only anonymous, aggregate data will be shared, and only upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

